Skip to content

Climb Bio, Inc. CLYM Q4 2024 Annual earnings

Reported March 25, 2025 · Before market open

EPS-$0.13Beat by $0.02
EPS estimate-$0.15

Next report

Aug 11, 2026 (In 1 week)
EPS estimate-$0.22

Financials

Q4 2024

Income statement

See full
Operating income-$10.9M-113%
Net income-$8.4M-131%

Balance sheet

See full
Cash & equivalents$87.2M-6.3%
Total debt$532.0K+52.4%
Total equity$211.9M+96.9%
Total assets$217.2M+96.6%

Cash flow

See full
Operating cash flow-$5.5M-483%
CapEx-
Free cash flow-$5.5M-483%

Valuation & ratios

Valuation

as of 12/31/24
See full
Market cap$121M
Enterprise value$34.31M

Returns & leverage

See full
Return on equity-46.3%+58.0pp
Debt / equity0.0×
Current ratio31.4×-7.5×

Versus estimates

Ask the moment Climb Bio, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Climb Bio, Inc. report Q4 2024 earnings?
Climb Bio, Inc. (CLYM) reported Q4 2024 earnings on March 25, 2025 before market open.
What were Climb Bio, Inc.'s Q4 2024 revenue and EPS?
Climb Bio, Inc. reported eps of $-0.13 for Q4 2024.
Did Climb Bio, Inc. beat estimates in Q4 2024?
EPS beat the consensus estimate of $-0.15 by $0.02.
Where can I find Climb Bio, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-044350) directly on SEC EDGAR. The filing index links above go to sec.gov.